

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Applicant:

Menachem RUBINSTEIN et al

Serial No.:

10/560,232

Filed:

March 24, 2006

For:

METHODS OF TREATING OBESITY AND

RELATED DISORDERS USING TELLURIUM

AND SELENIUM COMPOUNDS

Examiner:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Ar

Group Art Unit: 1614

Attorney

Docket: 31129

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted

Martin D. Moynihan

Registration No. 40,338

Dated: June 18, 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Unac. Complete if Known Substitute for form 1449A/PTO Application Number 10/560,232 INFORMATION DISCLOSURE Filing Date 24 March 2006 STATEMENT BY APPLICANT Menachem RUBINSTEIN et al First Named Inventor Art Unit (use as many sheets as necessary) Examiner Name unknown Attorney Docket Number 31129 1 of 2 Sheet U.S. PATENT DOCUMENTS Examiner Cite Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code² (if known) 06-11-1991 US-5,023,252 Hseih 12-21-1993 2 US-5,271,925 Sredni et al. 3 US-5,654,328 05-5-1997 Sredni et al. 4 US-6,403,641 06-11-2002 Heal et al. 05-5-2002 5 US-6,476,059 Jähne et al. 6 US-6,552,089 04-22-2003 Sredni et al. 09-23-2003 7 US-6,624,161 Hodson et al. 8 US-6,656,934 02-2-2003 Hodson et al. 9 07-20-2004 US-6,764,461 Mickley et al.

₽,

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Examiner Signature				Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE offormation unless it contains a valid OMB control number.

Onder the Paperwork Reduction Flor of 1725, no persons are required to respond to a concerton of information unit					Complete if Known			
Substitute for form 1449A/PTO					Application Number 10/560,232			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					Filing Date	24 March 2006		
					First Named Inventor	Menachem		
						RUBINSTEIN et al		
					Group Art Unit	1614		
					Examiner Name	unknowr	1	
Chast	12	· · · · · · · · · · · · · · · · · · ·	31129	12	Attorney Docket	31129		
Sheet	2		31129	2	Number	31129		
		OTHER I	PRIOR ART – NON	PATENT LITERA	ATURE DOCUMENT	S		
Examiner	Cite				rticle (when appropriate), tit			
Initials	No.1	item (book, magaz	zine, journal, serial sympo	sium, catalog, etc.) dat	e, page(s), volume-issue nur	nber(s),	T^2	
		publisher, city and/or country where published.						
	10	Kalechman et al. "The Antitumoral Effect of the Immunomodulator AS101 and						
					arcinoma", The Journa	l of		
			6: 1101 - 1109, 1996.					
	11	Kalechman et al.	. "Role of Endogenor	us Cytokines Secre	etion in Radioprotectio	n		
			e Immunomodulator ood, 85(6): 1555-156		loro(Dioxyethylene-0-			
-	12	Kalachman et al	"Delay of the Oncet	of Systematic Lu	pus Erythematosus Fol	lowing		
	12	Treatment With	the Immunomodulat	or ASIOI Associa	ation With IL-10 Inhibi	ition		
	1				ology, 159: 2658-2667,			
	13				S101 in Combination			
	13					W ILII		
	14		Cnacer Research, 51		Paclitaxel (Taxol) + AS	101 in		
	14							
		A Murine Model of B16 Melanoma: Association With Ras-Dependent Signal-						
Transduction Pathways", International Journal of Cancer, 86: 281-288, 2000.					The			
	15	Kalechman et al. "Radioprotective Effects of the Immunomodulator AS101", The						
	Journal of Immunology, 145(5): 1512-1517, 1990.							
	Campfield et al. "Recombinant Mouse OB Protein: Evidence for A Peripheral Signal							
	Linking Adiposity and Central Neural Networks", Science, 269: 546-546, 1995. 17 Pelleymounter et al. "Effects of the Obese Gene Product on Body Weight Regulation							
	' '		Science, 269: 540-5		t on body weight iteg	uiation		
	18				Protein Encoded by the	Ohese		
	16		269: 543-546, 1995.	ots of the Flashia i	Totelli Encoded by the	Obese		
	19			H1 Response in Ti	mor-Bearing Mice and	1		
	17				ational Cancer Institut			
		88(18): 1276-12		, souther or the r	acronal Cancer Institut	- ,		
-	20			odulator AS101 R	estores TH1 Type of			
	20				Mice", Cellular Immu	nology		
		184: 12-25, 1998						
	21			lator AS-101 Inhi	bits IL-10 Release and			
			and IL-1a Release I					
			llular Immunology,					
	22				AS-101) With Potentia			
			lication", Nature, 33					
·	23				Alopecia by AS101 in	Non-		
					atin and Etoposide", Jo			
			logy, 13(9): 2342-23		- p , • ·			
	24		sitional Cloning of th		ene and Its Human			
			ature, 372: 425-431,				İ	
- · · · · · · · · · · · · · · · · · · ·	1	† <u> </u>	· · · · · · · · · · · · · · · · · · ·					

Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.